- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02494804
Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Stage I-II Malignant Gliomas
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Changping Wu, M.D
- Phone Number: 8651968870978
- Email: wcpjjt@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed intracranial Grade 1 or 2 anaplastic glioma or glioblastoma (astrocytic tumor, anaplastic oligodendroglioma, or oligoastrocytoma).
Received prior standard radiation for a Grade 3 or 4 astrocytic tumor with a minimum cumulative dose of 40 Gy administered.
Completed at least one full cycle of temozolomide of 200 mg/m2/day administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.
Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits.
At least 18 years old. Both men and women must practice adequate contraception. Informed consent.
Exclusion Criteria:
Progressed while on temozolomide. Evidence of acute intracranial or intratumoral hemorrhage > Grade 1. Not recovered from the toxic effects of prior therapy. Pregnant or breast feeding. History of diabetes mellitus. Uncontrolled intercurrent illness. Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.
HIV positive. Diagnosis of another malignancy may exclude subject from study.
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Temozolomide
Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
|
Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
|
Other: Temozolomide+CIK
Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
|
The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- GLICIK001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytokine-Induced Killer Cells
-
China Meitan General HospitalCompletedPostoperative Complications | Colorectal Cancer | Survival | Cytokine-induced Killer Cells
-
The First People's Hospital of ChangzhouNot yet recruitingCytokine-Induced Killer Cells | Advanced Milignant Gliomas
-
University of Mississippi Medical CenterCompleted
-
Tanta UniversityMansoura University; Benha UniversityRecruitingRepeated Implantation Failure | ICSI Failure | uNatural Killer CellsEgypt
-
Jeadran N. Malagón-RojasNot yet recruitingStress, Psychological | Anxiety | Environmental Exposure | Cortisol Excess | Epigenetic Disorder | Natural Killer Cell Cytokine ProductionColombia
-
Institute of Cardiometabolism and Nutrition, FranceEnrolling by invitationInduced Pluripotent Stem CellsFrance
-
National Institutes of Health Clinical Center (CC)Withdrawn
-
Rambam Health Care CampusUnknown
-
ATGen Canada IncMaisonneuve-Rosemont HospitalCompletedNatural Killer Cell Cytokine ProductionCanada
-
Cynvenio BiosystemsUnknownTriple Negative Breast Cancer | BRCA Mutation | Natural Killer CellsUnited States
Clinical Trials on Temozolomide
-
University of SouthamptonBristol-Myers SquibbRecruitingCancer of Esophagus | Adenocarcinoma - GEJUnited Kingdom
-
Novartis PharmaceuticalsCompletedGlioblastomaAustralia, Spain, Canada, United States
-
Activartis BiotechCompleted
-
Guangzhou Medical UniversityUnknownSmall Cell Lung Cancer | Metastatic CarcinomaChina
-
Peking Union Medical College HospitalBeijing Tiantan Hospital; Tianjin Medical University General HospitalUnknownMalignant GliomasChina
-
Bradmer Pharmaceuticals Inc.Terminated
-
Yunpeng LiuUnknownExtensive Stage Small Cell Lung CancerChina
-
Haukeland University HospitalUniversity of Oslo; Oslo University Hospital; University Hospital of North Norway and other collaboratorsRecruiting
-
Merck Sharp & Dohme LLCTerminatedBreast Neoplasm | Brain Neoplasm | Second Neoplasm
-
Merck Sharp & Dohme LLCTerminatedCarcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm